中成药联合常规疗法治疗子宫内膜异位症的系统评价与贝叶斯网络Meta分析
该系统评价与贝叶斯网络Meta分析纳入148项随机对照试验(16198例),比较10种中成药联合常规疗法治疗子宫内膜异位症的疗效与安全性。结果显示,所有中成药均能有效提高总有效率并改善VAS疼痛评分,其中散结镇痛胶囊对总有效率提升最显著,丹莪妇康煎膏对降低VAS疼痛评分最有效,且部分中成药可降低激素及肝脏相关副作用风险。
要点
- 中成药联合常规疗法可提高子宫内膜异位症的总有效率并缓解疼痛。
- 散结镇痛胶囊在提高总有效率方面排名最高,丹莪妇康煎膏在降低VAS疼痛评分方面最优。
- 部分中成药(如血府逐瘀胶囊、散结镇痛胶囊等)可降低常规疗法相关不良反应风险。
核心结论
- 中成药可能有效治疗子宫内膜异位症,在总有效率、疼痛缓解、CA125降低和安全性方面表现优异,但需高质量研究验证。
研究设计与样本
- 系统评价与贝叶斯网络Meta分析,检索8个数据库至2024年10月,纳入148项随机对照试验,共16198例参与者,涉及10种中成药。
- 使用Cochrane RoB 2.0工具和CINeMA框架评估质量,注册于PROSPERO(CRD42023477523)。
主要发现
- 所有10种中成药均有效改善总有效率和VAS疼痛评分(与常规疗法比较)。
- 散结镇痛胶囊对总有效率改善最显著:对比激素治疗,风险比5.51(95%CI 4.21-7.2),SUCRA 86.3%,中等证据质量;对比GnRH-a,风险比4.74(95%CI 3.18-7),中等证据质量。
- 丹莪妇康煎膏对降低VAS疼痛评分最有效:对比激素治疗,平均差-2.1(95%CI -2.94至-1.29),SUCRA 78.8%,中等证据质量;对比GnRH-a,平均差-2.07(95%CI -2.73至-1.41),低证据质量。
- 中成药安全性较好,特别是在减少激素和肝脏相关副作用方面;血府逐瘀胶囊、散结镇痛胶囊、丹莪妇康煎膏、坤泰胶囊和桂枝茯苓胶囊相比常规疗法显示显著更低的不良事件相对风险。
关键数值与推荐
- 散结镇痛胶囊对比激素治疗的总有效率风险比5.51(95%CI 4.21-7.2),SUCRA 86.3%,中等证据质量。
- 散结镇痛胶囊对比GnRH-a的总有效率风险比4.74(95%CI 3.18-7),中等证据质量。
- 丹莪妇康煎膏对比激素治疗的VAS疼痛评分平均差-2.1(95%CI -2.94至-1.29),SUCRA 78.8%,中等证据质量。
- 丹莪妇康煎膏对比GnRH-a的VAS疼痛评分平均差-2.07(95%CI -2.73至-1.41),低证据质量。
临床怎么用
- 对于子宫内膜异位症患者,可考虑在常规疗法基础上联用中成药以提高总有效率并缓解疼痛。
- 若以缓解疼痛为主要目标,可优先考虑丹莪妇康煎膏;若以提高总有效率为主要目标,可优先考虑散结镇痛胶囊。
- 联用中成药可能降低激素和肝脏相关副作用风险,但需结合患者具体情况个体化决策。
局限性
- 研究结论为初步性,需要高质量研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Conventional hormonal treatments for endometriosis (EMs) are often associated with significant side effects. In recent years, many clinical trials and studies have highlighted the remarkable efficacy of Chinese patent medicines (CPMs) in alleviating endometriosis-related pain, reducing CA125 markers, regulating hormone levels, and preventing symptom recurrence. Numerous randomized controlled trials (RCTs) have been conducted on CPMs such as Shaofu Zhuyu Decoction (SZD), Dan'e Fukang Plaster (DFP), Sanjie Zhentong Capsule (SZC), Guizhi Fuling Capsule (GFC), Xiaojin Capsule (XC), Gongliu Xiao Capsule (GLXC), Xuefu Zhuyu Capsule (XZC), Jingtong Yushu Granule (JYG), Zhitong Huazheng Capsule (ZHC), and Kuntai Capsule (KTC) for the treatment of endometriosis. However, these studies have yet to be evaluated through a network meta-analysis (NMA) compliant with PRISMA standards. AIM OF THE STUDY: This study aimed to compare the efficacy and safety of ten CPMs for treating EMs through a NMA on RCTs. MATERIALS AND METHODS: PubMed, Cochrane, Embase, Web of Science, China National Knowledge Infrastructure, VIP Information, WanFang, and China Biomedicine databases were searched up to October 2024 for studies on the efficacy and safety of CPMs in treating EMs. Two researchers independently screened the studies, extracted data, and assessed quality using the Cochrane Risk of Bias 2.0 tool and the Confidence in Network Meta-Analysis framework. The NMA was conducted using Bayesian methods with StataSE and Rstudio, generating network diagrams, league tables, and Surface Under the Cumulative Ranking (SUCRA) line charts. This study was registered with PROSPERO (CRD42023477523). RESULTS: 148 eligible trials involving 10 CPMs and 16198 participants were included in this NMA; all subsequent estimates refer to the comparison with conventional therapies. All 10 CPMs effectively improved the total effective rate and VAS pain scores. SZC induced the most significant improvement in total effective rate(compared to hormone therapy: risk ratio 5.51, 95% confidence interval 4.21 to 7.2, SUCRA 86.3%, moderate confidence of evidence; compared to GnRH-a: 4.74, (3.18-7), moderate confidence of evidence). DFP proved to be the most effective CPM for lowering the VAS pain scores. (compared to hormone therapy: mean difference -2.1, (-2.94 to -1.29), 78.8%, moderate confidence of evidence; and GnRH-a (-2.07, (-2.73 to -1.41), low confidence of evidence). Moreover, this study demonstrated the safety of CPMs, particularly in reducing hormonal and liver-related side effects. Specific CPMs like XZC, SZC, DFP, KTC, and GFC showed markedly lower relative risks of adverse events when compared to conventional therapies. CONCLUSION: Chinese patent medicine may effectively treat EMs, excelling in total effective rate, pain relief, CA125 reduction, and safety. Nevertheless, these findings are preliminary and require validation through high-quality studies.
引用
- Huang W, Liu T, Yu Y, et al. Efficacy and safety of Chinese patent medicines combined with conventional therapies for endometriosis: A systematic review and bayesian network meta-analysis. J Ethnopharmacol. 2025. PMID: 39929398. doi:10.1016/j.jep.2025.119465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。